METTL3 and neoplasm: METTL3 is also upregulated in tumor-associated macrophages (TAMs) in patients with CRC with oxaliplatin resistance and downregulates TRAF5, inhibiting necroptosis (Lan et al., 2021), similar to its role in GC.